Optional ZOOM LINK
Meeting ID: 935 8655 7757
Passcode: 008066

Recent studies identifying antibodies from infected patients that can neutralize diverse strains of HIV have changed the landscape of vaccine design. While these broadly neutralizing antibodies (bNAbs) are the ultimate goal of any future vaccine, a range of approaches is being explored to generate this class of antibody de novo in patients. This presentation will focus on the use of viral vectors as a means of producing these bNAbs in vivo. We demonstrate that these antibodies are capable of suppressing actively replicating HIV infections, but their effectiveness is directly related to the ease with which the virus escapes selection pressure. Modulating the resistance benefit and fitness cost of these mutations directly impacts their therapeutic efficacy, revealing important principles for the design of novel therapeutic regimens capable of continuously suppressing HIV.

Hosted by Prof. Margie Ackerman